Skip to main content

Biorphen FDA Approval History

Last updated by Judith Stewart, BPharm on Nov 27, 2019.

FDA Approved: Yes (First approved October 21, 2019)
Brand name: Biorphen
Generic name: phenylephrine hydrochloride
Dosage form: Injection
Company: Eton Pharmaceuticals, Inc.
Treatment for: Hypotension

Biorphen (phenylephrine hydrochloride) injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of hypotension during anesthesia.

Development timeline for Biorphen

Oct 22, 2019Approval FDA Approves Biorphen (phenylephrine hydrochloride) Ready-to-Use Injection for Hypotension During Anesthesia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.